Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Adverum Biotechnologies, Inc. (ADVM : NSDQ)

• Company Description    Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum?s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. Number of Employees: 188

• Price / Volume Information    Yesterday's Closing Price: $0.86 Daily Weekly Monthly 20 Day Moving Average: 956,742 shares Shares Outstanding: 98.77 (millions) Market Capitalization: $84.45 (millions) Beta: 1.29 52 Week High: $3.86 52 Week Low: $0.80 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -24.34% -14.79% 12 Week -36.19% -29.86% Year To Date -51.42% -40.69%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 100 CARDINAL WAY - Redwood City,CA 94063 USA ph: 650-649-1004 fax: 650-329-8151 areddi@adverum.com http://www.adverum.com

• General Corporate Information    Officers Laurent Fischer - President and Chief Executive Officer Patrick Machado - Chairman of the Board Rupert D`Souza - Chief Financial Officer Soo Hong - Director Mark Lupher - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00773U108 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 98.77 Most Recent Split Date: (:1) Beta: 1.29 Market Capitalization: $84.45 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.38 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.56 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.30 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -31.03% vs. Previous Quarter: -8.57% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -46.82 12/31/21 - -39.98 09/30/21 - -37.80 ROA 03/31/22 - -33.27 12/31/21 - -30.35 09/30/21 - -30.35 Current Ratio 03/31/22 - 12.06 12/31/21 - 14.88 09/30/21 - 13.73 Quick Ratio 03/31/22 - 12.05 12/31/21 - 14.88 09/30/21 - 13.73 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - -1,940.53 09/30/21 - -1,968.65 Book Value 03/31/22 - 2.86 12/31/21 - 3.22 09/30/21 - 3.53 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©